Cloud-based Software as a Medical Device (SaMD) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cloud-based software as a medical device market size was valued at USD 2.94 billion in 2025 and is estimated to grow from USD 3.39 billion in 2026 to reach USD 6.88 billion by 2031, at a CAGR of 15.25% during the forecast period (2026-2031). This report is Segmented by Deployment (Cloud-Based, On-Premises, Hybrid), Device Type (Wearables, Smartphones, Pcs, Web Workstations), Application (Screening, Diagnostics, Chronic Disease, CDS), Clinical Specialty (Radiology, Cardiology, Oncology, Neurology, Others), End User (Hospitals, Ambulatory, Labs, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).

Global Cloud-based Software As A Medical Device (SaMD) Market Trends and Insights

Growing Clinical Adoption of AI-Enabled Diagnostic Software

The FDA reported 295 new AI-enabled medical device authorizations in 2025, bringing the cumulative total to 1,451 devices by December 30, 2025. This growth supported broader clinical familiarity with software used for diagnosis, triage, and image interpretation, although authorization still required local validation and implementation. Radiology accounted for 1,104 of the 1,451 cumulative FDA-listed AI-enabled devices by the end of 2025, underscoring its established role in clinical AI adoption. The 2024 PCCP guidance gave developers a defined route to describe planned model modifications and controls in a marketing submission, while cloud delivery supported version management, monitoring, and rollback processes.

Expansion of Remote Patient Monitoring and Virtual Care

Remote patient monitoring increasingly connected biosensor data with clinical review and patient support. The FDA launched the Technology-Enabled Meaningful Patient Outcomes pilot in December 2025, and Dexcom became its first participant on July 22, 2026. Dexcom’s program combined data from Dexcom G7 and Stelo biosensors with nutritional, sleep, and activity inputs for prediabetes and Type 2 diabetes interventions. A National Institute for Health and Care Research horizon scan identified 576 emerging wearable technologies under clinical evaluation for chronic disease management, including 25 novel technologies and 14 with a CE mark or FDA approval.

Cybersecurity, Data Privacy, and Cross-Border Health-Data Restrictions

The FDA issued final cybersecurity guidance for medical devices on June 27, 2025, covering cybersecurity design, documentation, and vulnerability management expectations for connected devices. The Quality Management System Regulation became effective on February 2, 2026, aligning FDA quality system requirements with ISO 13485:2016. These requirements increased compliance responsibilities for developers of cloud-hosted medical software. Data protection rules may require vendors to adjust where they store and process health information, while national requirements can limit the use of a single cloud architecture across every market. These obligations favor providers with established security, quality, and local compliance capabilities.

Other drivers and restraints analyzed in the detailed report include:

• Healthcare Provider Demand for Scalable Cloud Infrastructure
• Increasing Use of Real-World Data and Real-World Evidence
• Clinical Validation, Liability, and Workflow-Integration Complexity

Segment Analysis

Cloud-based deployment held 63.22% of the cloud-based software as a medical device market share in 2025. Health systems use cloud deployment to manage imaging archives, analytics capacity, and software update cycles without relying solely on local infrastructure. This model supports subscriptions and pay-per-scan arrangements, helping providers align technology spending with usage while avoiding local system replacements solely to access new analytical capacity. Vendors also use cloud deployment to distribute updates and monitor software performance across multiple sites.

On-premises deployment is forecast to expand at an 18.93% CAGR from 2026 to 2031. Demand comes from air-gapped government hospitals, defense health facilities, and markets with data sovereignty requirements. Hybrid systems provide a practical middle path for academic medical centers that retain local graphics processing units for model development while using cloud inference in clinical settings. GE HealthCare’s Genesis portfolio was introduced to support cloud and hybrid workflows alongside existing capital investments.

Wearable devices accounted for 35.23% of revenue in 2025, making them the largest category in this segmentation. Cardiac monitoring, continuous glucose sensing, and pulse oximetry remain key use cases. Wearables collect frequent measurements that can move to software platforms in the cloud-based software as a medical device market for review and clinical action. Their value increases when data enters structured clinical workflows that support review, assignment, and documentation.

Web-based clinical workstations are forecast to grow at a 17.67% CAGR from 2026 to 2031. Zero-footprint viewers and cloud-native picture archiving systems reduce the need for site-specific hardware. In March 2026, GE HealthCare received FDA 510(k) clearance for View, a cloud-based diagnostic viewer designed to provide browser access for radiologists. Smartphones, tablets, personal computers, and connected sensors complete the remaining access mix, with smartphones gaining relevance in lower-acuity primary care settings in Asia-Pacific.

Complete Report Scope:

• By Deployment
  • Cloud-Based
  • On-Premises
  • Hybrid
• By Device Type and Access Channel
  • Wearable Devices
  • Smartphones and Tablets
  • Personal Computers and Laptops
  • Web-Based Clinical Workstations
  • Connected Medical Devices and Sensors
  • Others
• By Application
  • Screening and Early Detection
  • Diagnostic Support
  • Monitoring and Alerting
  • Chronic Disease Management
  • Clinical Decision Support
  • Digital Therapeutics
  • Treatment Planning and Therapy Optimization
  • Medication Management and Dosing Support
  • Population Health and Risk Stratification
  • Clinical Trial and Drug Development Applications
  • Other Applications
• By Clinical Specialty
  • Cardiology
  • Radiology
  • Oncology
  • Neurology
  • Ophthalmology
  • Pathology
  • Respiratory Care
  • Diabetes Care
  • Mental and Behavioral Health
  • Women's Health
  • Other Clinical Specialties
• By End User
  • Hospitals and Clinics
  • Ambulatory and Specialist Centers
  • Diagnostic Laboratories
  • Imaging Centers
  • Academic and Research Institutions
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held a 40.56% revenue share in 2025, supported by the largest concentration of FDA-cleared AI-enabled medical devices and significant health system spending on digital care. The FDA’s list reached 1,451 authorized AI-enabled devices by the end of 2025. The United States finalized PCCP guidance in December 2024 and launched the TEMPO pilot in December 2025. Longstanding electronic health record, imaging, and laboratory data may support further algorithm development, although developers still need to manage data access, representativeness, and appropriate use.

Europe is shaped by EU MDR classification rules and a varied reimbursement environment. Germany’s DiGA pathway has allowed qualifying digital health applications to be prescribed and reimbursed through statutory health insurance, while France and Belgium have also developed digital health reimbursement pathways. The cloud-based software as a medical device market in Europe must address data protection, interoperability, and national assessment requirements. Germany, the United Kingdom, France, Italy, and Spain account for much of the region’s revenue, but suppliers still need to align reimbursement, procurement, and regulatory approaches with each national system. The European Health Data Space requirements will require manufacturers to plan for interoperability and logging capabilities in cloud platforms before 2029.

Asia-Pacific is forecast to register the highest regional CAGR of 17.56% from 2026 to 2031, driven by hospital digitization, regulatory development, and shortages of specialist physicians supporting demand for AI-assisted diagnosis in the cloud-based software as a medical device market. China released the revised YY/T 1406-2026 standard on March 17, 2026, covering risk management across the medical device software lifecycle and taking effect in March 2027.

List of Companies Covered in this Report:

• Aidoc Medical Ltd.
• AliveCor
• Alphabet Inc.
• Amazon Web Services, Inc.
• Apple
• Arterys Inc.
• Biofourmis Inc.
• Brain Lab
• BrightInsight, Inc.
• Digital Diagnostics
• Roche
• GE HealthCare Technologies Inc.
• Huma Therapeutics Limited
• iRhythm Technologies
• Koninklijke Philips
• Median Technologies SA
• Medtronic
• Microsoft
• MindMaze SA
• NVIDIA
• PathAI, Inc.
• Siemens Healthineers
• Singular Health Group Limited
• Tempus AI, Inc.
• Viz.ai, Inc.
• XUND Solutions GmbH

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support